ARNA:NSD-Arena Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 60.49

Change

-1.37 (-2.21)%

Market Cap

USD 3.75B

Volume

0.68M

Avg Analyst Target

USD 101.50 (+67.80%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase I clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Beacon Discovery; Boehringer Ingelheim International GmbH; Eisai Co., Ltd.; Eisai Inc.; and Aristea Therapeutics, Inc. for the development of RIST4721 for treatment of serious immune-mediated inflammatory diseases. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-02 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-6.99 (-1.98%)

USD141.98B 237.00 190.09
BNTX BioNTech SE

+11.86 (+3.61%)

USD79.30B 59.35 50.07
REGN Regeneron Pharmaceuticals, Inc

+2.52 (+0.44%)

USD61.22B 16.36 12.83
VRTX Vertex Pharmaceuticals Incorpo..

-3.26 (-1.62%)

USD52.23B 26.58 13.36
ALXN Alexion Pharmaceuticals, Inc

N/A

USD40.34B 59.23 42.56
GMAB Genmab A/S

+0.12 (+0.27%)

USD29.62B 33.28 3.77
BGNE BeiGene, Ltd

+10.83 (+3.42%)

USD29.25B N/A N/A
SGEN Seagen Inc

+0.85 (+0.55%)

USD27.91B 47.87 38.34
RPRX Royalty Pharma plc

-0.99 (-2.59%)

USD23.19B 31.49 13.92
ALNY Alnylam Pharmaceuticals, Inc

-0.98 (-0.55%)

USD21.03B N/A N/A

ETFs Containing ARNA

Symbol Name Weight Mer Price(Change) Market Cap
ROGS Hartford Multifactor Glob.. 0.00 % 0.34 %

N/A

USD0.02B
SBIO ALPS ETF Trust - ALPS Med.. 0.00 % 0.50 %

-0.12 (-0.28%)

USD0.23B
VALX Validea Market Legends ET.. 0.00 % 0.79 %

N/A

USD0.01B
MJ ETFMG Alternative Harvest.. 0.00 % 0.75 %

-0.08 (-0.45%)

USD1.61B
YOLO AdvisorShares Trust - Adv.. 0.00 % 0.75 %

+0.07 (+0.37%)

USD0.35B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -21.27% 39% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.27% 39% F 17% F
Trailing 12 Months  
Capital Gain -4.53% 54% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.53% 54% F 20% F
Trailing 5 Years  
Capital Gain 249.65% 83% B 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 249.65% 83% B 85% B
Average Annual (5 Year Horizon)  
Capital Gain 55.32% 78% C+ 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 55.32% 78% C+ 86% B
Risk Return Profile  
Volatility (Standard Deviation) 60.55% 52% F 29% F
Risk Adjusted Return 91.37% 98% A+ 91% A-
Market Capitalization 3.75B 90% A- 83% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 6.40 51% F 81% B-
Price/Book Ratio 3.46 48% F 41% F
Price / Cash Flow Ratio -10.63 63% D 74% C
EV/EBITDA 3.52 43% F 88% B+
Management Effectiveness  
Return on Equity -40.78% 64% D 32% F
Return on Invested Capital -38.11% 61% D- 20% F
Return on Assets -24.96% 47% F 14% F
Debt to Equity Ratio 3.81% 67% D+ 81% B-
Technical Ratios  
Short Ratio 7.40 22% F 13% F
Short Percent 5.21% 58% F 37% F
Beta 0.53 85% B 85% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector